Farxiga (Dapagliflozin) Cost in Florida: Prices, Insurance, and Savings in 2026

What Does Farxiga Actually Cost at Florida Pharmacies in 2026?

The average cash-pay price for a 30-day supply of Farxiga (dapagliflozin) 10 mg at Florida retail pharmacies is approximately $620 per month [1]. This figure reflects the AstraZeneca manufacturer list price and is consistent across major chains including CVS, Walgreens, and Publix locations statewide. The price has remained relatively stable since the drug's original FDA approval in 2014 for type 2 diabetes [2].

Prices can vary by $30 to $80 between pharmacies in the same Florida metro area. Independent pharmacies in Tampa, Jacksonville, and Miami occasionally price dapagliflozin lower than national chains, though availability is inconsistent. Costco pharmacies (which do not require a membership for prescription purchases in Florida) sometimes offer a modest discount. Without insurance or a manufacturer coupon, most Florida residents should expect to pay close to the full list price. A GoodRx or RxSaver coupon can reduce the cost to roughly $480 to $540 at select locations, though these prices fluctuate weekly. Patients filling at mail-order pharmacies may save an additional 5% to 10% on 90-day supplies [1].

The SGLT2 inhibitor class as a whole carries high list prices. Jardiance (empagliflozin), the primary competitor, lists at approximately $610 to $630 per month. Neither drug has a generic equivalent available in the United States as of May 2026.

Does Florida Medicaid Cover Farxiga?

Florida Medicaid does not include Farxiga on its preferred drug list for type 2 diabetes management alone. Patients with a primary diagnosis of T2D who request dapagliflozin through a Florida Medicaid managed care plan will typically receive a denial at the pharmacy level [3].

The picture shifts for patients with heart failure or chronic kidney disease. Farxiga earned FDA approval for reducing the risk of cardiovascular death and hospitalization for heart failure with reduced ejection fraction (HFrEF) in 2020, and for slowing eGFR decline in chronic kidney disease in 2021 [2]. In DAPA-HF (N=4,744), dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) [4]. These expanded indications opened a pathway for prior authorization requests under Florida Medicaid when the prescribing indication is HF or CKD rather than T2D.

To pursue Medicaid coverage for a non-T2D indication, the prescribing physician must submit a prior authorization form documenting the specific diagnosis code (ICD-10 I50.x for heart failure or N18.x for CKD), lab values supporting the diagnosis, and evidence that first-line therapies have been tried or are contraindicated. Approval rates vary by managed care organization. Patients enrolled in Humana Healthy Horizons, Sunshine Health, or Molina Healthcare of Florida should contact their plan's pharmacy benefits line directly to confirm current formulary status.

Which Florida Insurance Plans Cover Farxiga?

Most major commercial insurance plans in Florida place Farxiga on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position, resulting in copays between $40 and $150 per month depending on the specific plan design [1].

Blue Cross Blue Shield of Florida (Florida Blue) lists dapagliflozin as a Tier 3 preferred brand for type 2 diabetes, heart failure, and CKD indications. Aetna Florida plans generally require step therapy through metformin before approving Farxiga for T2D. UnitedHealthcare covers dapagliflozin but may require prior authorization for the CKD indication specifically. Cigna plans in the Florida market typically place Farxiga on Tier 3 with a $50 to $75 copay after deductible.

Medicare Part D coverage for Farxiga in Florida varies significantly by plan. Under the Inflation Reduction Act provisions that took effect in 2025, annual out-of-pocket prescription drug costs for Medicare beneficiaries are capped at $2,000 [5]. This cap helps Florida seniors who take Farxiga alongside other brand-name medications, as their total annual drug spending is now limited regardless of list prices. The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as preferred second-line agents for patients with T2D and established cardiovascular or kidney disease, which can support coverage appeals [6].

Dr. Silvio Inzucchi, professor of medicine at Yale School of Medicine, has stated: "SGLT2 inhibitors have become indispensable in the management of type 2 diabetes complicated by heart failure or CKD. Their cardiorenal benefits are independent of glucose lowering" [6].

How the AstraZeneca Savings Card Works in Florida

AstraZeneca offers a manufacturer savings card for Farxiga that can reduce the copay to as little as $0 per month for eligible commercially insured patients [1]. The card is accepted at all major Florida pharmacy chains.

Eligibility requirements are straightforward. Patients must have commercial (private) insurance that covers Farxiga, be residents of the United States, and not be enrolled in any federal or state healthcare program including Medicare, Medicaid, Tricare, or VA benefits. The card covers up to a set annual maximum (typically $1,800 to $2,400 per year in savings) and can be renewed annually. Patients activate the card online at the AstraZeneca patient portal or receive it directly from their prescribing provider.

For uninsured Florida patients, AstraZeneca also operates the AZ & Me patient assistance program, which provides Farxiga at no cost to qualifying individuals whose household income falls below 400% of the federal poverty level [1]. Application requires income documentation and a prescription from a U.S.-licensed provider. Processing typically takes two to four weeks.

A common error: patients assume the savings card eliminates the need for insurance. It does not. The card functions as a copay offset applied on top of existing insurance coverage. Uninsured patients need the separate patient assistance program.

Is Compounded Dapagliflozin Legal in Florida?

Compounded dapagliflozin is available through licensed 503A compounding pharmacies in Florida under strict oversight from the Florida Board of Pharmacy [7]. This route is legal when a prescriber writes a patient-specific prescription and the compounding pharmacy holds a valid Florida permit.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications from bulk pharmaceutical ingredients for individual patients based on valid prescriptions [7]. Florida enforces additional state-level requirements: the pharmacy must document a genuine prescriber-patient relationship, the compounded product must not be an essentially copy of a commercially available drug (unless the prescriber documents a clinical difference such as an allergy to an inactive ingredient), and the pharmacy must comply with United States Pharmacopeia (USP) chapters 795 and 797 for non-sterile and sterile compounding respectively.

The practical reality is nuanced. Because Farxiga is commercially available as a finished tablet, most compounding pharmacies will require the prescriber to document a specific clinical reason for compounding (such as a need for a non-standard dose, liquid formulation, or avoidance of a specific excipient). A blanket "cost savings" rationale does not satisfy FDA or Florida Board of Pharmacy requirements for 503A compounding of a commercially available product.

Patients considering this route should verify that their compounding pharmacy is licensed, accredited by the Pharmacy Compounding Accreditation Board (PCAB) or a comparable body, and willing to provide a certificate of analysis for the compounded product.

Can You Get Farxiga Through Telehealth in Florida?

Yes. Florida law permits licensed prescribers to prescribe Farxiga via telehealth. The state finalized permanent telehealth legislation in 2023 that allows board-certified physicians, nurse practitioners, and physician assistants to establish patient relationships and prescribe medications through audio-video consultations [8].

Dapagliflozin is not a controlled substance and carries no DEA scheduling restrictions that would limit telehealth prescribing. A provider licensed in Florida (or holding a Florida telehealth registration if licensed in another state) can evaluate a patient remotely, review lab work, and send the prescription electronically to any Florida pharmacy.

Several telehealth platforms operating in Florida offer metabolic health consultations that include SGLT2 inhibitor prescribing. Patients should confirm that the platform's providers are Florida-licensed and that the consultation includes a review of kidney function (serum creatinine, eGFR) and blood pressure before initiating dapagliflozin. The Farxiga prescribing information contraindicates use in patients with an eGFR <20 mL/min/1.73 m² for the diabetes indication, though the threshold differs for heart failure [2].

The DAPA-CKD trial (N=4,304) demonstrated that dapagliflozin reduced the composite of sustained eGFR decline of 50% or greater, end-stage kidney disease, or death from renal or cardiovascular causes by 39% versus placebo (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [9]. These results, published in the New England Journal of Medicine, supported the expanded CKD indication and reinforced the importance of kidney function monitoring during treatment.

Comparing Farxiga vs. Jardiance Costs in Florida

Both SGLT2 inhibitors carry nearly identical list prices in Florida. Jardiance (empagliflozin) 10 mg or 25 mg lists at approximately $610 to $630 per month, while Farxiga 10 mg lists at $620 [1]. Cost differences between the two drugs are driven almost entirely by insurance formulary placement rather than manufacturer pricing.

Florida Blue and Humana commercial plans tend to prefer Farxiga. Aetna and Cigna lean toward Jardiance in many plan designs, though this varies by employer group. The clinical distinction matters: Farxiga holds FDA approvals for T2D, HFrEF, and CKD, while Jardiance is approved for T2D and HFrEF but also carries a heart failure indication that includes HFpEF (preserved ejection fraction) based on the EMPEROR-Preserved trial [10].

The 2024 ADA Standards of Care do not preferentially recommend one SGLT2 inhibitor over another, stating: "The choice of a specific SGLT2 inhibitor should be guided by FDA-approved indications, patient comorbidities, formulary coverage, and cost" [6]. For Florida patients whose primary concern is out-of-pocket cost, the deciding factor is which drug their specific plan places on a lower tier. Switching between SGLT2 inhibitors does not require a washout period and can be done at the next fill date.

Practical Steps to Lower Your Farxiga Cost in Florida

Reducing out-of-pocket spending on dapagliflozin in Florida follows a specific sequence. Start with insurance verification. Call the number on the back of your insurance card and ask the pharmacy benefits team three questions: Is dapagliflozin on formulary? What tier? Does it require prior authorization or step therapy?

If your plan covers Farxiga with a copay above $50, activate the AstraZeneca savings card before your next fill. The card stacks on top of insurance and can eliminate the remaining copay entirely for commercially insured patients [1].

If you are uninsured, apply to the AZ & Me patient assistance program. Gather your most recent tax return, a completed application form (available from your provider or online), and your prescription. Submit by fax or mail. While waiting for approval, ask your provider about a 30-day starter sample.

For Medicare beneficiaries, compare Part D plans during open enrollment using the Medicare Plan Finder tool at medicare.gov. Filter by "dapagliflozin" to see which plans in your Florida ZIP code offer the lowest total annual cost. The $2,000 annual out-of-pocket cap applies regardless of plan choice, but monthly copay structures differ substantially [5].

If all other options fail, ask your prescriber whether a 503A compounding pharmacy is appropriate for your clinical situation. This requires documented justification beyond cost alone.